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Patients Undergoing Percutaneous
Coronary Intervention
Is There a Role for Pharmacodynamic Testing?*Dominick J. Angiolillo, MD, PHD, Jung Rae Cho, MDA spirin is an irreversible inhibitor of theplatelet cyclooxygenase (COX)-1 enzyme,which in adjunct to a P2Y12 receptor
antagonist, represents the cornerstone of treatment
for patients undergoing percutaneous coronary in-
terventions (PCI) (1). Despite the clinical beneﬁts,
ischemic events may continue to occur, which may
be attributed in part to variability in pharmacody-
namic (PD) response to antiplatelet therapy (2). In-
vestigations assessing the PD effects of the P2Y12
receptor inhibitor clopidogrel in the setting of PCI
have consistently shown an association between
high on-treatment platelet reactivity and risk of
ischemic recurrences, including stent thrombosis
(3). However, PD studies evaluating aspirin effects
have been subject to critique, and the clinical impact
of these PD ﬁndings also have resulted in conﬂicting
data (4–6). Overall, these results have hampered the
level of enthusiasm toward studies assessing the
clinical implications of the PD effects of aspirin.SEE PAGE 863In this issue of the Journal, Mayer et al. (7) report
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ASPI (Intracoronary Stenting and Antithrombotic
Regimen—Aspirin and Platelet Inhibition) study (7).
Patients (n ¼ 7,090) pretreated with a 500 mg intra-
venous (IV) dose of aspirin underwent PD testing
prior to PCI by means of the Multiplate analyzer
(Roche Diagnostics, Basel, Switzerland). Patients in
the upper quintile distribution of arachidonic acid-
induced platelet aggregation (n ¼ 1,414), corre-
sponding to a cut-off value of 203 aggregation units
(AU)  min, were deﬁned as having high on-aspirin
treatment platelet reactivity (HAPR). At 1 year, the
primary composite endpoint of death from any cause
or stent thrombosis (deﬁnite or probable) was nearly
2-fold higher in HAPR patients than in non-HAPR
patients. HAPR was conﬁrmed to be an independent
predictor of the primary outcome in a multivariate
analysis, and the results also were supported by
propensity score matching assessment. Ultimately,
statistical modeling using different metrics showed
that the presence of HAPR allowed further risk
stratiﬁcation of the patients. The investigators are to
be commended for the conduct of this study. Major
strengths include the very large cohort of patients,
the long-term follow-up with a clinically relevant
primary endpoint, the detailed statistical approach,
and the homogeneous conditions under which the PD
assessments were performed. However, several con-
siderations need to be addressed.
A full PD effect of aspirin and complete COX-1-
mediated inhibition of platelet thromboxane pro-
duction can be achieved with low-dose therapy (8).
In fact, the prevalence of “aspirin resistance” is
approximately close to null when assays speciﬁcally
measuring COX-1 activity are used, challenging the
concept of “aspirin resistance” (2,9). Many available
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873assays are not speciﬁc for measuring platelet COX-1
activity, which may explain the broad prevalence
of “aspirin resistance” in published reports and the
inconsistent association with clinical correlates
(2,4–6,9). These observations highlight some meth-
odological considerations of the ISAR-ASPI study.
Only 1 PD assay was used to identify HAPR, which
also was arbitrarily deﬁned (7). A receiver operating
characteristic curve analysis to deﬁne the optimal
HAPR cut-off value in this large study cohort would
have been of interest. In addition, PD assessments
were conducted at a single time point prior to PCI
in patients treated with an IV aspirin formulation.
PD ﬁndings may vary according to the aspirin
formulation and dosing regimen, and they also can
change over time (2,4,8). Thus, the prognostic im-
plications of a more commonly used oral mainte-
nance regimen remain elusive. Differences in P2Y12
receptor antagonist usage and levels of adenosine
diphosphate-induced platelet aggregation also may
have represented potential confounders.
These observations may contribute to why, in
another large-scale study (n ¼ 8,665), the ADAPT-DES
(Assessment of Dual AntiPlatelet Therapy with Drug-
Eluting Stent) trial, which considered a pre-deﬁned
cut-off value using a different assay (VerifyNow;
Accumetrics, San Diego, California) assessed the day
after PCI, showed a different prevalence rate (5.6%) of
HAPR (6). Importantly, HAPR was not associated with
any ischemic endpoint but was inversely related to
bleeding. Interestingly, in the ISAR-ASPI study, pa-
tients with HAPR paradoxically had numerically more
in-hospital bleeding than non-HAPR patients, which
was signiﬁcant in the propensity score matching
analysis. Indeed, knowing the impact of HAPR on
long-term bleeding complications would have been of
interest. It cannot thus be excluded that the increased
bleeding potential could have contributed to the dif-
ferences in mortality observed.
Although the results of the ISAR-ASPI study do not
argue against the prognostic value of HAPR as assessed
in this study cohort, the main challenge remains
focused on what to do with this adjunctive informa-
tion. Studies assessing the clinical implications of
modifying treatment in patients with inadequate
PD response to antiplatelet therapy have beendisappointing to date (10,11). Potential treatment op-
tions in the acute phase for HAPR patients undergoing
PCI include the use of IV aspirin and glycoprotein
IIb/IIIa inhibitors (GPI). However, the use of IV aspirin
among HAPR patients pretreated with an oral aspirin
regimen has not shown to be associated with any
clinical beneﬁt (12). Moreover, despite its acute bene-
ﬁts, the use of the GPI tiroﬁban did not translate into
long-term beneﬁts among poor responders to aspirin
(13). In the maintenance phase of therapy, strategies to
increase aspirin-induced effects include high-
maintenance and twice-daily aspirin dosing regimens
(9,14). However, the safety and efﬁcacy of these stra-
tegies tailored to HAPR patients have yet to be tested.
The potential impact of ADP-mediated signaling on
HAPR also has led to suggest the potential role of
P2Y12-inhibiting strategies in these patients (15).
However, adjunctive clopidogrel therapy did not
reduce cardiovascular events among aspirin-treated
patients with incomplete inhibition of thromboxane
biosynthesis (16). Moreover, in a prospective, ran-
domized study, switching HAPR patients to clopidog-
rel did not affect clinical outcomes (17). Ultimately, the
impact of tailored use of the novel P2Y12 receptor in-
hibitors prasugrel and ticagrelor, which have been
suggested to exert some degree of modulating effects
on thromboxane generation (18), remains unknown.
In summary, HAPR, as measured in the ISAR-ASPI
study, is a biomarker associated with an increased
risk of worse outcomes and allows better risk strat-
iﬁcation of patients undergoing PCI. However, in-
vestigations corroborating these ﬁndings are
warranted, particularly in light of the controversial
ﬁndings of the prognostic value of PD measures of
aspirin-induced antiplatelet effects. Ultimately,
deﬁning the treatment strategies tailored to these
high-risk patients that can improve outcomes, which
thus far has yielded unsatisfactory results, remains the
ultimate objective that would enable this biomarker
to be incorporated into routine clinical practice.
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